|
1
|
Kalia LV and Lang AE: Parkinson's disease.
Lancet. 386:896–912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andican G, Konukoglu D, Bozluolcay M,
Bayulkem K, Firtiina S and Burcak G: Plasma oxidative and
inflammatory markers in patients with idiopathic Parkinson's
disease. Acta Neurol Belg. 112:155–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mullin S and Schapira AH: Pathogenic
mechanisms of neurodegeneration in Parkinson disease. Neurol Clin.
33:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maiti P, Manna J and Dunbar GL: Current
understanding of the molecular mechanisms in Parkinson's disease:
Targets for potential treatments. Transl Neurodegener. 6:282017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moss EG: MicroRNAs: Hidden in the genome.
Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma L, Wei L, Wu F, Hu Z, Liu Z and Yuan W:
Advances with microRNAs in Parkinson's disease research. Drug Des
Devel Ther. 7:1103–1113. 2013.PubMed/NCBI
|
|
8
|
Quinlan S, Kenny A, Medina M, Engel T and
Jimenez-Mateos EM: MicroRNAs in neurodegenerative diseases. Int Rev
Cell Mol Biol. 334:309–343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu Y, Zhen J and Lu Z: Synergetic
neuroprotective effect of docosahexaenoic acid and aspirin in
SH-Y5Y by inhibiting miR-21 and activating RXRalpha and PPARalpha.
DNA Cell Biol. 36:482–489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su C, Yang X and Lou J: Geniposide reduces
alpha-synuclein by blocking microRNA-21/lysosome-associated
membrane protein 2A interaction in Parkinson disease models. Brain
Res 1644. 98–106. 2016. View Article : Google Scholar
|
|
11
|
Singer TP, Ramsay RR, McKeown K, Trevor A
and Castagnoli NE Jr: Mechanism of the neurotoxicity of
1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology.
49:17–23. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng J, Liu Q, Rao MS and Zeng X: Using
human pluripotent stem cell-derived dopaminergic neurons to
evaluate candidate Parkinson's disease therapeutic agents in MPP+
and rotenone models. J Biomol Screen. 18:522–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ge X, Li W, Huang S, Yin Z, Yang M, Han Z,
Han Z, Chen F, Wang H, Lei P and Zhang J: Increased miR-21-3p in
injured brain microvascular endothelial cells following traumatic
brain injury aggravates blood-brain barrier damage by promoting
cellular apoptosis and inflammation through targeting MAT2B. J
Neurotrauma. 36:1291–1305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oh SE, Park HJ, He L, Skibiel C, Junn E
and Mouradian MM: The Parkinson's disease gene product DJ-1
modulates miR-221 to promote neuronal survival against oxidative
stress. Redox Biol. 19:62–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Sun Y and Chen J: Identification of
critical genes and miRNAs associated with the development of
parkinson's disease. J Mol Neurosci. 65:527–535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong G and Nass R: miRNAs and their
putative roles in the development and progression of Parkinson's
disease. Front Genet. 3:3152013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Titze-de-Almeida R and Titze-de-Almeida
SS: miR-7 replacement therapy in parkinson's disease. Curr Gene
Ther. 18:143–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lotharius J, Dugan LL and O'Malley KL:
Distinct mechanisms underlie neurotoxin-mediated cell death in
cultured dopaminergic neurons. J Neurosci. 19:1284–1293. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Devathasan G, Chong PN, Puvanendran K, Lun
KC and Wong PK: Low-dose bromocriptine therapy in severe
Parkinson's disease. Clin Neuropharmacol. 7:231–237. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yadava N and Nicholls DG: Spare
respiratory capacity rather than oxidative stress regulates
glutamate excitotoxicity after partial respiratory inhibition of
mitochondrial complex I with rotenone. J Neurosci. 27:7310–7317.
2007. View Article : Google Scholar : PubMed/NCBI
|
